The dual effects of common chemotherapies in cancer, either as a cytotoxic drug or as a sensitizer to the effect of TRAIL and MSC-TRAIL have also been demonstrated in several tumor xenografts including those of brain cancer [40], hepatocellular carcinoma [41], breast cancer [42] and NSCLC [43]. This evidence concerns the gene TNFSF10 and breast cancer.